The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents

Neuropharmacology

Volumn 99, Issue , 2015, Pages 256-263

  Gentzel, Renee C ^a   Toolan, Dawn ^a   Roberts, Rhonda ^a   Koser, Amy Jo ^a   Kandebo, Monika ^a   Hershey, James ^a   Renger, John J ^a   Uslaner, Jason ^a   Smith, Sean M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Catalepsy; Haloperidol; Immediate early genes; Phosphodiesterase inhibitors; Schizophrenia

Indexed keywords

2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; EARLY GROWTH RESPONSE FACTOR 1; ENKEPHALIN; HALOPERIDOL; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; SUBSTANCE P; UNCLASSIFIED DRUG; 2-((4-(1-METHYL-4-PYRIDIN-4-YL-1H-PYRAZOL-3-YL)PHENOXY)METHYL)QUINOLINE; ACTIVITY REGULATED CYTOSKELETAL-ASSOCIATED PROTEIN; CYTOSKELETON PROTEIN; DOPAMINE RECEPTOR BLOCKING AGENT; DRD2 PROTEIN, RAT; EGR1 PROTEIN, RAT; NERVE PROTEIN; PDE10A PROTEIN, RAT; PHOSPHODIESTERASE INHIBITOR; PROTEIN C FOS; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARC GENE; ARTICLE; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; EGR 1 GENE; ENZYME INHIBITION; GENE EXPRESSION; GLOBUS PALLIDUS; IMMEDIATE EARLY GENE; LOW DRUG DOSE; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; RAT; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION PROFILING; METABOLISM; NERVE CELL; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA; WISTAR RAT;

ANIMALS; CATALEPSY; CORPUS STRIATUM; CYTOSKELETAL PROTEINS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EARLY GROWTH RESPONSE PROTEIN 1; ENKEPHALINS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HALOPERIDOL; MALE; NERVE TISSUE PROTEINS; NEURONS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROTO-ONCOGENE PROTEINS C-FOS; PYRAZOLES; QUINOLINES; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, DOPAMINE D2; SUBSTANCE P; SUBSTANTIA NIGRA;

EID: 84939185313     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.05.024     Document Type: Article

References (49)

1. A. Abi-Dargham, and M. Laruelle Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies Eur. Psychiatry 20 1 2005 15 27
2. R.L. Albin, A.B. Young, and J.B. Penney The functional anatomy of basal ganglia disorders Trends Neurosci. 12 10 1989 366 375
3. C. Arango, G. Garibaldi, and S.R. Marder Pharmacological approaches to treating negative symptoms: a review of clinical trials Schizophr. Res. 150 2-3 2013 346 352
4. A.T. Bender, and J.A. Beavo Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use Pharmacol. Rev. 58 3 2006 488 520
5. A. Carlsson Antipsychotic drugs, neurotransmitters, and schizophrenia Am. J. Psychiatry 135 2 1978 165 173
6. S.Z. Chao, and et al. D(1) dopamine receptor stimulation increases GluR1 phosphorylation in postnatal nucleus accumbens cultures J. Neurochem. 81 5 2002 984 992
7. T.A. Chappie, C.J. Helal, and X. Hou Current landscape of phosphodiesterase 10A (PDE10A) inhibition J. Med. Chem. 55 17 2012 7299 7331
8. M. Conti, and J. Beavo Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling Annu. Rev. Biochem. 76 2007 481 511
9. T.M. Coskran, and et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species J. Histochem. Cytochem. 54 11 2006 1205 1213
10. P.F. Durieux, S.N. Schiffmann, and A. de Kerchove d'Exaerde Differential regulation of motor control and response to dopaminergic drugs by D1R and D2R neurons in distinct dorsal striatum subregions Embo J. 31 3 2012 640 653
11. S. Eftekhari, and et al. Localization of CGRP receptor components, CGRP, and receptor binding sites in human and rhesus cerebellar cortex Cerebellum 12 6 2013 Dec 937 949 10.1007/s12311-013-0509-4
12. K. Fujishige, and et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A) J. Biol. Chem. 274 26 1999 18438 18445
13. C.R. Gerfen, and et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons Science 250 4986 1990 1429 1432
14. G. Glavan, D. Sket, and M. Zivin Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-parkinsonian rats Mol. Pharmacol. 61 2 2002 360 368
15. S.M. Grauer, and et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia J. Pharmacol. Exp. Ther. 331 2 2009 574 590
16. G.A. Graveland, and M. DiFiglia The frequency and distribution of medium-sized neurons with indented nuclei in the primate and rodent neostriatum Brain Res. 327 1-2 1985 307 311
17. M.F. Green, and K.H. Nuechterlein The MATRICS initiative: developing a consensus cognitive battery for clinical trials Schizophr. Res. 72 1 2004 1 3
18. J.E. Gresack, and et al. Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating Psychopharmacol. Berl. 231 10 2014 2189 2197
19. S.N. Haber The primate basal ganglia: parallel and integrative networks J. Chem. Neuroanat. 26 4 2003 317 330
20. P.D. Harvey, and et al. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness J. Clin. Psychiatry 65 3 2004 361 372
21. R.S. Keefe, and et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial Arch. Gen. Psychiatry 64 6 2007 633 647
22. R.S. Kern, and et al. NIMH-MATRICS survey on assessment of neurocognition in schizophrenia Schizophr. Res. 72 1 2004 11 19
23. A.V. Kravitz, and et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry Nature 466 7306 2010 622 626
24. B. Ky, and P.J. Shughrue Methods to enhance signal using isotopic in situ hybridization J. Histochem. Cytochem. 50 8 2002 1031 1037
25. V. Lakics, E.H. Karran, and F.G. Boess Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues Neuropharmacology 59 6 2010 367 374
26. D.A. Lewis, and J.A. Lieberman Catching up on schizophrenia: natural history and neurobiology Neuron 28 2 2000 325 334
27. K. Loughney, and et al. Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase Gene 234 1 1999 109 117
28. A.A. Megens, and et al. PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways Pharmacol. Res. Perspect. 2 4 2014 e00057
29. A. Nishi, and et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum J. Neurosci. 28 42 2008 10460 10471
30. A. Nishi, M. Kuroiwa, and T. Shuto Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons Front. Neuroanat. 5 2011 43
31. A. Parent, and L.N. Hazrati Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop Brain Res. Brain Res. Rev. 20 1 1995 91 127
32. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates fourth ed. 1998 Academic Press Charles Watson
33. E. Perez-Costas, M. Melendez-Ferro, and R.C. Roberts Basal ganglia pathology in schizophrenia: dopamine connections and anomalies J. Neurochem. 113 2 2010 287 302
34. E. Piccart, and et al. Impaired appetitively as well as aversively motivated behaviors and learning in PDE10A-deficient mice suggest a role for striatal signaling in evaluative salience attribution Neurobiol. Learn. Mem. 95 3 2011 260 269
35. I.T. Raheem, and et al. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia Bioorg. Med. Chem. Lett. 22 18 2012 5903 5908
36. C.J. Schmidt, and et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia J. Pharmacol. Exp. Ther. 325 2 2008 681 690
37. T.F. Seeger, and et al. Immunohistochemical localization of PDE10A in the rat brain Brain Res. 985 2 2003 113 126
38. J.A. Siuciak The role of phosphodiesterases in schizophrenia: therapeutic implications CNS Drugs 22 12 2008 983 993
39. J.A. Siuciak, and et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis Neuropharmacology 51 2 2006 386 396
40. S.M. Smith, and et al. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey Neuropharmacology 64 2013 215 223
41. S.H. Soderling, S.J. Bayuga, and J.A. Beavo Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A Proc. Natl. Acad. Sci. U. S. A. 96 12 1999 7071 7076
42. F. Sotty, and et al. Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons J. Neurochem. 109 3 2009 766 775
43. C.A. Strick, and et al. Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A Neuropharmacology 58 2 2009 444 451
44. S. Threlfell, and et al. Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation J. Pharmacol. Exp. Ther. 328 3 2009 785 795
45. C. Tsutsumi, and et al. The evolution of antipsychotic switch and polypharmacy in natural practice-a longitudinal perspective Schizophr. Res. 130 1-3 2011 40 46
46. P.R. Verhoest, and et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia J. Med. Chem. 52 16 2009 5188 5196
47. D.R. Weinberger, K.F. Berman, and T.N. Chase Mesocortical dopaminergic function and human cognition Ann. N. Y. Acad. Sci. 537 1988 330 338
48. Z. Xie, and et al. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase Neuroscience 139 2 2006 597 607
49. Y. Yoshida, and et al. Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen Brain Res. 639 1 1994 139 148